Ulipristal | CAS#159811-51-5

MedKoo Cat#: 341363 | Name: Ulipristal

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ulipristal is a bichemical.

Chemical Structure

Ulipristal

CAS#159811-51-5

Theoretical Analysis

MedKoo Cat#: 341363

Name: Ulipristal

CAS#: 159811-51-5

Chemical Formula: C28H35NO3

Exact Mass: 433.2617

Molecular Weight: 433.59

Elemental Analysis: C, 77.56; H, 8.14; N, 3.23; O, 11.07

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 350.00	2 weeks
50mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

159811-51-5 126784-99-4 (acetate)

Synonym

Ulipristal; VA-2914; VA 2914; VA2914; PGL-4001; PGL 4001; PGL4001; CDB 3236; Deacetyl CDB 2914;

IUPAC/Chemical Name

11beta-(4-(Dimethylamino)phenyl)-17-hydroxy-19-norpregna-4,9-diene-3,20-dione

InChi Key

HKDLNTKNLJPAIY-WKWWZUSTSA-N

InChi Code

InChI=1S/C28H35NO3/c1-17(30)28(32)14-13-25-23-11-7-19-15-21(31)10-12-22(19)26(23)24(16-27(25,28)2)18-5-8-20(9-6-18)29(3)4/h5-6,8-9,15,23-25,32H,7,10-14,16H2,1-4H3/t23-,24+,25-,27-,28-/m0/s1

SMILES Code

CC([C@@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(CCC4=C3[C@@H](C5=CC=C(N(C)C)C=C5)C[C@]12C)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 433.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Haeger KO, Lamme J, Cleland K. State of emergency contraception in the U.S., 2018. Contracept Reprod Med. 2018 Sep 5;3:20. doi: 10.1186/s40834-018-0067-8. eCollection 2018. Review. PubMed PMID: 30202545; PubMed Central PMCID: PMC6123910. 2: Donnez J. Liver injury and ulipristal acetate: an overstated tragedy? Fertil Steril. 2018 Sep;110(4):593-595. doi: 10.1016/j.fertnstert.2018.06.044. PubMed PMID: 30196943. 3: Zigler RE, Madden T, Ashby C, Wan L, McNicholas C. Ulipristal Acetate for Unscheduled Bleeding in Etonogestrel Implant Users: A Randomized Controlled Trial. Obstet Gynecol. 2018 Aug 17. doi: 10.1097/AOG.0000000000002810. [Epub ahead of print] PubMed PMID: 30130351. 4: Edelman AB, Jensen JT, McCrimmon S, Messerle-Forbes M, O'Donnell A, Hennebold JD. Combined oral contraceptive interference with the ability of ulipristal acetate to delay ovulation: A prospective cohort study. Contraception. 2018 Aug 14. pii: S0010-7824(18)30396-2. doi: 10.1016/j.contraception.2018.08.003. [Epub ahead of print] PubMed PMID: 30118684. 5: De Gasperis-Brigante C, Singh SS, Vilos G, Kives S, Murji A. Pregnancy Outcomes Following Ulipristal Acetate for Uterine Fibroids: A Systematic Review. J Obstet Gynaecol Can. 2018 Aug;40(8):1066-1076.e2. doi: 10.1016/j.jogc.2018.05.020. Review. PubMed PMID: 30103881. 6: Santoro A, Angelico G, Arciuolo D, Inzani F, Fanfani F, Romualdi D, Scambia G, Zannoni GF. Failure of ulipristal acetate treatment as an indication for uterine malignancy: Two case reports. Medicine (Baltimore). 2018 Aug;97(31):e11532. doi: 10.1097/MD.0000000000011532. PubMed PMID: 30075519; PubMed Central PMCID: PMC6081078. 7: Gan N, Sun Q, Zhang M, Tang P, Zhao L, Xie T, Zhang Y, Li H. Insights into the interaction of ulipristal acetate and human serum albumin using multi-spectroscopic methods, molecular docking, and dynamic simulation. J Biomol Struct Dyn. 2018 Jul 30:1-24. doi: 10.1080/07391102.2018.1502686. [Epub ahead of print] PubMed PMID: 30056779. 8: Shin SJ, Kim J, Lee S, Baek J, Lee JE, Cho C, Ha E. Ulipristal acetate induces cell cycle delay and remodeling of extracellular matrix. Int J Mol Med. 2018 Oct;42(4):1857-1864. doi: 10.3892/ijmm.2018.3779. Epub 2018 Jul 17. PubMed PMID: 30015921; PubMed Central PMCID: PMC6108884. 9: Shortrede JE, Montt-Guevara MM, Pennacchio G, Finiguerra M, Giannini A, Genazzani AD, Simoncini T. Ulipristal Acetate Interferes With Actin Remodeling Induced by 17β-Estradiol and Progesterone in Human Endometrial Stromal Cells. Front Endocrinol (Lausanne). 2018 Jun 27;9:350. doi: 10.3389/fendo.2018.00350. eCollection 2018. PubMed PMID: 30013514; PubMed Central PMCID: PMC6036300. 10: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK500655/ PubMed PMID: 29999714. 11: Illingworth BJG, Hirsch M, Duffy JMN. Ulipristal Acetate for Treatment of Symptomatic Uterine Leiomyomas: A Randomized Controlled Trial. Obstet Gynecol. 2018 Jul;132(1):215. doi: 10.1097/AOG.0000000000002718. PubMed PMID: 29939915. 12: Tuschy B, Gabbert M, Weiss C, Hornemann A, Wuhrer A, Sütterlin M, Berlit S. Changes in sexuality during ulipristal acetate treatment in women with symptomatic uterine fibroids. Eur J Obstet Gynecol Reprod Biol. 2018 Sep;228:106-110. doi: 10.1016/j.ejogrb.2018.06.027. Epub 2018 Jun 17. PubMed PMID: 29920429. 13: Elger W, Schneider B, Killeen Z, Jewgenow K, Dehnhard M, Friedrich M, Santhamma B, Wedemeyer R, Nickisch K. Model for Hormonal Emergency Contraception (HEC) in cycling and mated guinea pigs - Studies with the Progesterone Receptor Modulators (PRM) Ulipristal Acetate (UPA/CDB2914) and EC317. J Steroid Biochem Mol Biol. 2018 Oct;183:152-158. doi: 10.1016/j.jsbmb.2018.06.009. Epub 2018 Jun 11. PubMed PMID: 29902513. 14: Oscoz-Jaime S, Larrea-García M, Mitxelena-Eceiza MJ, Abián-Franco N. Progesterone Autoimmune Dermatitis Responding to Ulipristal Acetate. Actas Dermosifiliogr. 2018 May 31. pii: S0001-7310(18)30088-7. doi: 10.1016/j.ad.2017.11.016. [Epub ahead of print] English, Spanish. PubMed PMID: 29861040. 15: Czuczwar P, Stepniak A, Milart P, Paszkowski T, Wozniak S. Comparison of the influence of three fibroid treatment options: supracervical hysterectomy, ulipristal acetate and uterine artery embolization on ovarian reserve - an observational study. J Ovarian Res. 2018 Jun 1;11(1):45. doi: 10.1186/s13048-018-0420-1. PubMed PMID: 29859107; PubMed Central PMCID: PMC5984745. 16: Courtoy GE, Donnez J, Ambroise J, Arriagada P, Luyckx M, Marbaix E, Dolmans MM. Gene expression changes in uterine myomas in response to ulipristal acetate treatment. Reprod Biomed Online. 2018 Aug;37(2):224-233. doi: 10.1016/j.rbmo.2018.04.050. Epub 2018 May 7. PubMed PMID: 29807764. 17: Cleland K, Wagner B, Batur P, McNamara M, Wu J, Rothberg MB. The politics of place: Presidential voting patterns and providers' prescription of emergency contraception. Contraception. 2018 Sep;98(3):237-242. doi: 10.1016/j.contraception.2018.05.013. Epub 2018 May 18. PubMed PMID: 29778587. 18: Collins JC, Schneider CR, Moles RJ. Emergency contraception supply in Australian pharmacies after the introduction of ulipristal acetate: a mystery shopping mixed-methods study. Contraception. 2018 Sep;98(3):243-246. doi: 10.1016/j.contraception.2018.04.020. Epub 2018 May 9. PubMed PMID: 29752924. 19: Melis GB, Neri M, Piras B, Paoletti AM, Ajossa S, Pilloni M, Marotto MF, Corda V, Saba A, Giancane E, Mais V. Vilaprisan for treating uterine fibroids. Expert Opin Investig Drugs. 2018 May;27(5):497-505. doi: 10.1080/13543784.2018.1471134. Epub 2018 May 7. Review. PubMed PMID: 29718788. 20: Lira-Albarrán S, Durand M, Barrera D, Vega C, Becerra RG, Díaz L, García-Quiroz J, Rangel C, Larrea F. A single preovulatory administration of ulipristal acetate affects the decidualization process of the human endometrium during the receptive period of the menstrual cycle. Mol Cell Endocrinol. 2018 Nov 15;476:70-78. doi: 10.1016/j.mce.2018.04.010. Epub 2018 Apr 27. PubMed PMID: 29709683.